← Search & browse all drugs

sodium iodohippurate (123I)

V09CX01

Forms & Strengths

Sterile aqueous solution for IV injection, 123I‑iodohippurate (sodium iodohippurate)
Typical supplied activity 0.5–5 GBq per vial depending on manufacturer

Adult Dosing

IV bolus 3–5 MBq (0.08–0.14 mCi) for planar renal cortical imaging; up to 10 MBq for SPECT/CT
Inject rapidly, followed by 10 mL saline flush

Pediatric Dosing

Weight‑based 0.5–1 MBq/kg IV (maximum 5 MBq for infants)
Adjust activity for age‑related renal function; use lowest activity that yields diagnostic quality

Indications

Renal cortical scintigraphy to assess differential renal function
Detection of renal scarring or cortical defects (e.g., reflux nephropathy)
Evaluation of renal tubular function and effective renal plasma flow

Mechanism of Action

123I‑iodohippurate is actively taken up by proximal tubular cells via organic anion transporters
Retention reflects renal cortical perfusion and tubular function; minimal glomerular filtration

Contraindications

Known hypersensitivity to iodinated compounds or sodium iodohippurate
Pregnancy unless benefit outweighs radiation risk
Breast‑feeding – discontinue or pump and discard milk for 24 h

Adverse Reactions

Mild nausea, vomiting, or flushing during injection
Transient rash or urticaria; rare anaphylactoid reaction
Radiation exposure – very low but contraindicated in pregnant women

Drug Interactions

Drugs inhibiting tubular secretion (e.g., probenecid, cimetidine, diuretics) may reduce renal uptake
High‑dose iodine or iodinated contrast may compete for transport and lower image quality

Curated Content: Needs Vetting Before Put to Clinical Use